FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3072079143> ?p ?o ?g. }

• W3072079143 endingPage "3372" @default.
• W3072079143 startingPage "3366" @default.
• W3072079143 abstract "Abstract Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with daclatasvir in treating patients with COVID-19. Methods Patients with a positive nasopharyngeal swab for SARS-CoV-2 on RT–PCR or bilateral multi-lobar ground-glass opacity on their chest CT and signs of severe COVID-19 were included. Subjects were divided into two arms with one arm receiving ribavirin and the other receiving sofosbuvir/daclatasvir. All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine. The primary endpoint was time from starting the medication until discharge from hospital with secondary endpoints of duration of ICU stay and mortality. Results Sixty-two subjects met the inclusion criteria, with 35 enrolled in the sofosbuvir/daclatasvir arm and 27 in the ribavirin arm. The median duration of stay was 5 days for the sofosbuvir/daclatasvir group and 9 days for the ribavirin group. The mortality in the sofosbuvir/daclatasvir group was 2/35 (6%) and 9/27 (33%) for the ribavirin group. The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17 (95% CI 0.04–0.73, P = 0.02) and the number needed to treat for benefit was 3.6 (95% CI 2.1–12.1, P &lt; 0.01). Conclusions Given these encouraging initial results, and the current lack of treatments proven to decrease mortality in COVID-19, further investigation in larger-scale trials seems warranted." @default.
• W3072079143 created "2020-08-24" @default.
• W3072079143 creator A5003745190 @default.
• W3072079143 creator A5008403728 @default.
• W3072079143 creator A5008998185 @default.
• W3072079143 creator A5020548362 @default.
• W3072079143 creator A5024027725 @default.
• W3072079143 creator A5024665813 @default.
• W3072079143 creator A5030572475 @default.
• W3072079143 creator A5037701728 @default.
• W3072079143 creator A5046954297 @default.
• W3072079143 creator A5049195384 @default.
• W3072079143 creator A5051095964 @default.
• W3072079143 creator A5060462160 @default.
• W3072079143 creator A5060610100 @default.
• W3072079143 creator A5062295276 @default.
• W3072079143 creator A5063213631 @default.
• W3072079143 creator A5063434056 @default.
• W3072079143 creator A5066930019 @default.
• W3072079143 creator A5071297639 @default.
• W3072079143 creator A5074075059 @default.
• W3072079143 creator A5079339791 @default.
• W3072079143 creator A5086697726 @default.
• W3072079143 creator A5090003369 @default.
• W3072079143 date "2020-08-19" @default.
• W3072079143 modified "2023-10-01" @default.
• W3072079143 title "The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19" @default.
• W3072079143 cites W2022898511 @default.
• W3072079143 cites W3004404619 @default.
• W3072079143 cites W3012379316 @default.
• W3072079143 cites W3012588029 @default.
• W3072079143 cites W3012994592 @default.
• W3072079143 cites W3015429854 @default.
• W3072079143 cites W3015608194 @default.
• W3072079143 cites W3018023298 @default.
• W3072079143 cites W3023915741 @default.
• W3072079143 cites W3027630905 @default.
• W3072079143 cites W4248347735 @default.
• W3072079143 doi "https://doi.org/10.1093/jac/dkaa331" @default.
• W3072079143 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7529105" @default.
• W3072079143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32812051" @default.
• W3072079143 hasPublicationYear "2020" @default.
• W3072079143 type Work @default.
• W3072079143 sameAs 3072079143 @default.
• W3072079143 citedByCount "77" @default.
• W3072079143 countsByYear W30720791432020 @default.
• W3072079143 countsByYear W30720791432021 @default.
• W3072079143 countsByYear W30720791432022 @default.
• W3072079143 countsByYear W30720791432023 @default.
• W3072079143 crossrefType "journal-article" @default.
• W3072079143 hasAuthorship W3072079143A5003745190 @default.
• W3072079143 hasAuthorship W3072079143A5008403728 @default.
• W3072079143 hasAuthorship W3072079143A5008998185 @default.
• W3072079143 hasAuthorship W3072079143A5020548362 @default.
• W3072079143 hasAuthorship W3072079143A5024027725 @default.
• W3072079143 hasAuthorship W3072079143A5024665813 @default.
• W3072079143 hasAuthorship W3072079143A5030572475 @default.
• W3072079143 hasAuthorship W3072079143A5037701728 @default.
• W3072079143 hasAuthorship W3072079143A5046954297 @default.
• W3072079143 hasAuthorship W3072079143A5049195384 @default.
• W3072079143 hasAuthorship W3072079143A5051095964 @default.
• W3072079143 hasAuthorship W3072079143A5060462160 @default.
• W3072079143 hasAuthorship W3072079143A5060610100 @default.
• W3072079143 hasAuthorship W3072079143A5062295276 @default.
• W3072079143 hasAuthorship W3072079143A5063213631 @default.
• W3072079143 hasAuthorship W3072079143A5063434056 @default.
• W3072079143 hasAuthorship W3072079143A5066930019 @default.
• W3072079143 hasAuthorship W3072079143A5071297639 @default.
• W3072079143 hasAuthorship W3072079143A5074075059 @default.
• W3072079143 hasAuthorship W3072079143A5079339791 @default.
• W3072079143 hasAuthorship W3072079143A5086697726 @default.
• W3072079143 hasAuthorship W3072079143A5090003369 @default.
• W3072079143 hasBestOaLocation W30720791431 @default.
• W3072079143 hasConcept C126322002 @default.
• W3072079143 hasConcept C159047783 @default.
• W3072079143 hasConcept C203092338 @default.
• W3072079143 hasConcept C2522874641 @default.
• W3072079143 hasConcept C2776408679 @default.
• W3072079143 hasConcept C2776979040 @default.
• W3072079143 hasConcept C2777100407 @default.
• W3072079143 hasConcept C2778390639 @default.
• W3072079143 hasConcept C2780040827 @default.
• W3072079143 hasConcept C535046627 @default.
• W3072079143 hasConcept C71924100 @default.
• W3072079143 hasConcept C90924648 @default.
• W3072079143 hasConceptScore W3072079143C126322002 @default.
• W3072079143 hasConceptScore W3072079143C159047783 @default.
• W3072079143 hasConceptScore W3072079143C203092338 @default.
• W3072079143 hasConceptScore W3072079143C2522874641 @default.
• W3072079143 hasConceptScore W3072079143C2776408679 @default.
• W3072079143 hasConceptScore W3072079143C2776979040 @default.
• W3072079143 hasConceptScore W3072079143C2777100407 @default.
• W3072079143 hasConceptScore W3072079143C2778390639 @default.
• W3072079143 hasConceptScore W3072079143C2780040827 @default.
• W3072079143 hasConceptScore W3072079143C535046627 @default.
• W3072079143 hasConceptScore W3072079143C71924100 @default.
• W3072079143 hasConceptScore W3072079143C90924648 @default.
• W3072079143 hasIssue "11" @default.

• next